Search
ferric carboxymaltose
Indications:
- intravenous iron replacement for iron-deficiency
- reduces hospitalization burden in stabilized, iron-deficient patients with heart failure due to LV systolic dysfunction [1,3]
Adverse effects:
- transient hypophosphatemia* [2]
* due to increased FGF23 causing phosphaturia & a decrease in formation of calcitriol [2]
General
hematologic agent
References
- Ponikowski P et al. on behalf of the AFFIRM-AHF Investigators.
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure:
A multicentre, double-blind, randomised, controlled trial.
Lancet 2020 Nov 13; [e-pub].
PMID: 33197395
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32339-4/fulltext
- Medical Knowledge Self Assessment Program (MKSAP) 19.
American College of Physicians, Philadelphia 2021
- Ponikowski P, Mentz RJ, Hernandez AF et al.
Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an
individual patient data meta-analysis.
Eur Heart J. 2023 Aug 26:ehad586
PMID: 37632415
https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad586/7251520